Physician profile
Rafael E Gonzalez
NPI 1033238019
$18,714.93
in general payments reported to CMS, 2019-2025
29 companies · $3,732 in 2025
The $3,732 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,592 · 2020: $740 · 2021: $2,059 · 2022: $3,567 · 2023: $3,557 · 2024: $2,468 · 2025: $3,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,673 · Travel and Lodging: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,672.93 |
| Travel and Lodging | $2,084.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $4,279.43 | 2021-2025 | Evoque, Pascal, Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $3,378.04 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Medtronic, INC. | $3,152.78 | 2021-2025 | Corevalve Evolut R, Abre, Hawkone |
| Abbott Laboratories | $3,094.18 | 2019-2025 | Jot Dx, Amplatzer Amulet, Optis |
| Abiomed | $819.18 | 2019-2025 | Impella |
| Biotronik INC. | $608.32 | 2022-2023 | Orsiro Mission |
| Inari Medical, INC. | $557.70 | 2022 | |
| Impulse Dynamics (USA) INC. | $534.27 | 2022-2024 | Optimizer, Optimizer |
| Teleflex LLC | $503.39 | 2019-2025 | Guideliner, Manta, Turnpike |
| Boston Scientific Corporation | $413.91 | 2020-2025 | Emerge Push, Rotapro, General - Vascular Intervention |
| Astrazeneca Pharmaceuticals LP | $225.14 | 2019-2021 | |
| Siemens Medical Solutions USA, INC. | $169.42 | 2023-2025 | Artis Icono Floor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $141.95 | 2019-2025 | Lifevest |
| Terumo Medical Corporation | $130.91 | 2019-2021 | |
| Medtronic Vascular, INC. | $123.84 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $121.78 | 2025 | Flowtriever, Artix Mt, Clottriever Bold Catheter |
| Cardiovascular Systems INC. | $96.45 | 2019-2021 | |
| Philips North America LLC | $80.84 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $51.71 | 2024-2025 | |
| Recor Medical INC | $49.00 | 2024 | Paradise Renal Denervation System |
| Ekos Corporation | $27.15 | 2019 | |
| Amgen INC. | $26.49 | 2019 | |
| Saranas, INC. | $24.36 | 2022 | |
| Cook Medical LLC | $24.04 | 2024 | Zilver Ptx |
| Angiodynamics, INC. | $23.82 | 2025 | Alphavac |
| Gilead Sciences, INC. | $15.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.69 | 2021 | |
| Heartflow, INC. | $14.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.